Telix Pharmaceuticals Us
UEI: NMRHMBK4YTH7
• CAGE: 8CP27
Overview
Awardee Type
Parent
Company Description
Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation.
Name
Telix Pharmaceuticals Us
Website
Headquarters
Fishers, IN
United States
United States
Most Recent Award
Feb. 12, 2026
Calculating
Federal contract recipient
TELIX PHARMACEUTICALS US INC
(UEI NMRHMBK4YTH7, CAGE 8CP27)
is headquartered in Fishers IN.
Its primary registered NAICS is 325412 Pharmaceutical Preparation Manufacturing.
The corporation
was founded in August 2017 and
federally registered in
June 2019.
Federal Award Analysis
Telix Pharmaceuticals Us federal award history
$-
Contracts
$-
Subcontracts
$-
Grants
$-
Subgrants
$-
Total
No Results
Calculating
Calculating
No Results
Calculating
Calculating
No Results
Calculating
Calculating
| Year | Contracts | Subcontracts | Grants | Subgrants |
|---|
No Results
Calculating
Calculating
No Results
Calculating
Calculating
Federal Registration and Certifications
Legal Name
TELIX PHARMACEUTICALS US INC
UEI
NMRHMBK4YTH7
CAGE Code
8CP27
Primary NAICS
SBA Certifications
None
Self Certifications
For Profit Organization, Manufacturer of Goods
Entity Structure
Corporate Entity (Not Tax Exempt)
Purpose of Registration
Federal Contracts and Assistance
Date Founded
Aug. 14, 2017
Initial Registration
June 19, 2019
Last Registration
Jan. 30, 2026
Registration Activation
Jan. 30, 2026
Registration Expiration
Jan. 30, 2027
Fiscal Year End
December 31
Reported Entity Types
For Profit Organization
Manufacturer of Goods
Manufacturer of Goods
State of Incorporation
DE
Country of Incorporation
USA
Employees
1001-1500
Reported NAICS
Reported PSC
Accepts Credit Cards
No
People
Vendor contacts at Telix Pharmaceuticals Us
GSA Schedules and Price Lists
- Telix Pharmaceuticals Us
- PoP: 8/14/22 - 8/14/27
- Type: Pharmaceuticals and Drugs (FSS 65 I B)
- Obligated: $7,984,575
- Telix Pharmaceuticals Us
- PoP: 4/16/22 - 10/14/22 (Ended)
- Obligated: $364,200